content:vigabatrin

Old Revisions

These are the older revisons of the current document. To revert to an old revision, select it from below, click Edit this page and save it.

  • 2020/02/23 18:46 Vigabatrin – [Adverse drug reactions] icna +130 B (current)
  • 2020/02/23 18:15 Show differences to current revisions Vigabatrin – [Dosage and titration] icna +6 B
  • 2020/02/23 18:14 Show differences to current revisions Vigabatrin – [Main disadvantages] icna +380 B
  • 2020/02/23 18:04 Show differences to current revisions Vigabatrin – [Main disadvantages] icna +14 B
  • 2020/02/23 18:01 Show differences to current revisions Vigabatrin – [Considerations in women] icna +241 B
  • 2020/02/23 18:00 Show differences to current revisions Vigabatrin – [Authorised indications] icna +130 B
  • 2020/02/23 17:58 Show differences to current revisions Vigabatrin – [Vigabatrin] icna +91 B
  • 2020/02/23 17:56 Show differences to current revisions Vigabatrin – [Clinical applications] icna +210 B
  • 2020/02/23 17:54 Show differences to current revisions Vigabatrin – [Adverse drug reactions] icna +33 B
  • 2020/02/23 17:46 Show differences to current revisions Vigabatrin – [Drug interactions] icna -6 B
  • 2020/02/23 17:45 Show differences to current revisions Vigabatrin – [Main mechanisms of action] icna -62 B
  • 2020/02/23 17:39 Show differences to current revisions Vigabatrin – [Main disadvantages] icna -3.6 KB
  • 2020/02/23 17:39 Show differences to current revisions Vigabatrin – created icna +10.3 KB
  • content/vigabatrin.txt
  • Last modified: 5 months ago
  • by icna